Guselkumab 100mg/1ml solution for injection pre-filled disposable devices
Requires a prescription from a doctor or prescriber
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Guselkumab
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Guselkumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Guselkumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Guselkumab on the MHRA register
Tremfya 100mg/1ml solution for injection pre-filled pens
WHO defined daily dose (DDD)
1.79 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(13)
Guselkumab for treating moderate to severe plaque psoriasis (TA521)
Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)
Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Risankizumab for treating moderate to severe plaque psoriasis (TA596)
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Spondyloarthritis in over 16s: diagnosis and management (NG65)
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Ulcerative colitis: management (NG130)
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Psoriasis: assessment and management (CG153)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 11 · Randomised trials: 33 · 2014–2026
Showing the 50 most relevant studies, sorted by most relevant.
Andrew Blauvelt, Andrew Blauvelt, Kim Papp, et al.
British Journal of Dermatology, 2019
- Psoriasis
- Quality of Life
- Antibodies, Monoclonal, Humanized
Brian G. Feagan, Bruce E. Sands, William J. Sandborn, et al.
The Lancet. Gastroenterology & hepatology, 2023
- COVID-19
- Adenocarcinoma
- Colitis, Ulcerative
Fan Bai, Gang Gang Li, Qingmin Liu, et al.
Journal of Immunology Research, 2019
- Ustekinumab
- Network Meta-Analysis
- Antibodies, Monoclonal
Kristian Reich, April W. Armstrong, Richard G. Langley, et al.
The Lancet, 2019
- Antibodies, Monoclonal
- Biological Products
- Psoriasis
Philip J. Mease, Proton Rahman, Alice B. Gottlieb, et al.
The Lancet, 2020
- Arthritis, Psoriatic
- Antirheumatic Agents
- Antibodies, Monoclonal, Humanized
Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin, et al.
British Journal of Dermatology, 2017
- Ustekinumab
- Patient Reported Outcome Measures
- Antibodies, Monoclonal
Atul Deodhar, Philip Helliwell, Wolf‐Henning Boehncke, et al.
The Lancet, 2020
- Tumor Necrosis Factor-alpha
- Arthritis, Psoriatic
- Antibodies, Monoclonal, Humanized
Jawad Bilal, Adam Berlinberg, Sandipan Bhattacharjee, et al.
Journal of Dermatological Treatment, 2018
- Antibodies, Monoclonal
- Dermatologic Agents
- Psoriasis
Tadashi Terui, Satomi Kobayashi, Yukari Okubo, et al.
JAMA Dermatology, 2019
Silvio Danese, Remo Panaccione, Brian G. Feagan, et al.
The Lancet. Gastroenterology & hepatology, 2023
- Biological Products
- Crohn Disease
- Ustekinumab
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
15 to 18 days
Mechanism
Guselkumab targets the p19 alpha subunit of IL-23.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
100mg
Half-life
15 to 18 days
[L52700]
Volume of distribution
13.5 L
[L52700]
Metabolism
[L52700]
Elimination
Clearance
0.516 L
[L52700]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
- the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy.
[L52700]
- the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis.
[L52700]
- the treatment of adults with moderately to severely active ulcerative colitis.
[L52700]
- the treatment of adults with moderately to severely active Crohn’s disease.
[L52700]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 681 interactions
[L52700]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L52700]
[L52700]
[L52700]
[L52700]
[L52700]
Proteins and enzymes this drug interacts with in the body
PMID:11114383
Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4 .
PMID:29287995 PMID:32474165 PMID:33606986
This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A .
PMID:12023369
In turn, participates in the early and effective intracellular bacterial clearance .
PMID:32474165
Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells PMID:17676044
ATC L04AC16
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Guselkumab
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72